Drugs Containing Excipient (Inactive Ingredient) ACETYL TRIBUTYL CITRATE

Generic drugs containing ACETYL TRIBUTYL CITRATE excipient

Company	Ingredient	NDC	Excipient
The Procter & Gamble Manufacturing Company	omeprazole magnesium	84126-300	ACETYL TRIBUTYL CITRATE
The Procter & Gamble Manufacturing Company	omeprazole magnesium	84126-301	ACETYL TRIBUTYL CITRATE

Acetyl Tributyl Citrate Market Dynamics, Pharmaceutical Demand, and Financial Trajectory

Last updated: September 24, 2026

Acetyl tributyl citrate, or ATBC, is a nonphthalate citrate ester used primarily as a plasticizer in pharmaceutical coatings, soft capsules, food-contact materials, medical devices, cosmetics, and flexible polymers. Its pharmaceutical market is specialized and fragmented. Public companies generally do not report ATBC revenue separately, so a defensible standalone global market size or company-level sales forecast is not publicly available. Financial performance is driven more by formulation conversion, polymer demand, regulatory preferences, and raw-material costs than by prescription-drug volume.

What is acetyl tributyl citrate and how is it used in pharmaceuticals?

Acetyl tributyl citrate is identified by Chemical Abstracts Service number 77-90-7. It is produced by esterifying citric acid with n-butanol and acetylating the resulting tributyl citrate. The product is a clear, low-volatility liquid that acts as a plasticizer.

In pharmaceutical applications, ATBC is used mainly in polymeric dosage-form components rather than as an active pharmaceutical ingredient. Typical applications include:

Pharmaceutical application	Function of ATBC	Commercial relevance
Enteric film coatings	Improves flexibility and reduces brittleness	Established use in oral solid dosage forms
Modified-release coatings	Plasticizes acrylic or cellulosic polymers	Supports release-control formulation design
Soft gelatin and other capsules	Improves polymer flexibility where formulation-compatible	More limited and formulation-specific
Drug-delivery films	Adjusts mechanical properties and film formation	Niche development activity
Medical-device polymers	Plasticizer for selected polymer systems	Larger adjacent market than pharmaceuticals

ATBC is selected when a formulation developer wants a citrate-based, nonphthalate plasticizer with low volatility and compatibility with coating polymers. The choice depends on polymer type, solvent system, coating temperature, migration profile, residual solvents, stability, and the required dissolution or release profile.

What is the pharmaceutical regulatory status of acetyl tributyl citrate?

ATBC is an excipient, not an FDA-approved drug. It does not receive an independent New Drug Application approval, biologics license, or marketing exclusivity period.

Regulatory status is product- and route-specific:

• Pharmaceutical sponsors must establish that the selected grade is suitable for the intended dosage form and route.
• FDA inactive-ingredient listings can support precedent for particular uses, but an entry does not automatically approve every concentration, route, or formulation.
• Excipient identity, purity, residual solvents, elemental impurities, microbial quality, and manufacturing controls remain part of the drug product’s regulatory file.
• European submissions generally evaluate excipients under the applicable quality and safety requirements for the finished medicinal product.
• Pharmaceutical manufacturers may request supplier qualification packages, certificates of analysis, stability data, change-control commitments, and toxicological documentation.

The FDA Inactive Ingredient Database is the most relevant public source for determining whether an excipient has precedent in approved drug products. The database should be interpreted at the dosage-form and route level rather than as a blanket authorization for all uses (U.S. Food and Drug Administration, n.d.-a).

Does acetyl tributyl citrate have FDA Orange Book exclusivity?

No. ATBC is not an active drug substance and is not listed in the Orange Book as a standalone pharmaceutical product. It has no independent patent term, Hatch-Waxman exclusivity, Paragraph IV challenge pathway, or generic-drug exclusivity period.

Patent exposure can still arise indirectly through:

• A drug product formulation patent that identifies ATBC as one of several plasticizers.
• A controlled-release or enteric-coating patent that covers a specific polymer and excipient combination.
• A manufacturing process patent for a finished dosage form.
• Supplier know-how covering purity, odor, color, residual solvent, or process control.

A supplier’s composition or manufacturing patent would not create Orange Book exclusivity for ATBC itself.

How large is the acetyl tributyl citrate pharmaceutical market?

No audited public source provides a reliable standalone market size for pharmaceutical-grade ATBC. Commercial market reports often combine pharmaceutical, food, cosmetics, coatings, toys, packaging, and other plasticizer uses. Those aggregated figures cannot be used as a pharmaceutical revenue estimate.

The pharmaceutical segment is likely smaller than the broader ATBC market because:

1. ATBC demand is spread across several industrial end markets.
2. A pharmaceutical coating uses relatively small quantities per finished product.
3. Formulation demand is concentrated among coating-material suppliers and contract manufacturers.
4. Qualification requirements make substitution slower but also limit the number of approved applications.
5. Suppliers usually report citrate esters as a product family rather than disclosing ATBC sales.

The broader commercial market is influenced by demand for nonphthalate plasticizers, flexible packaging, medical materials, coatings, and consumer products. Pharmaceutical demand is more stable but less volume-intensive than packaging and polymer applications.

What companies manufacture or supply acetyl tributyl citrate?

The market has a combination of established specialty-chemical producers, regional manufacturers, distributors, and pharmaceutical excipient suppliers.

Supplier or supplier group	Market position	Likely competitive basis
Vertellus and its Citroflex portfolio	Established citrate-ester supplier	Product history, regulatory documentation, global customer support
Jungbunzlauer	Major citrate-derivative producer	Integrated citrate chemistry, quality systems, international reach
Chinese and other Asian manufacturers	Regional and export supply	Price, capacity, flexible commercial terms
Specialty distributors	Supply-chain and inventory role	Local availability, regulatory support, smaller order sizes
Pharmaceutical excipient distributors	Formulation and qualification support	Documentation, customer service, multi-region supply

Vertellus markets citrate ester plasticizers under the Citroflex brand, including ATBC-related products. Jungbunzlauer produces citrate esters and other citric-acid derivatives for industrial and pharmaceutical applications. Product nomenclature, grades, and regulatory support differ by supplier, so a brand name should not be treated as proof of pharmaceutical suitability (Vertellus, n.d.; Jungbunzlauer, n.d.).

How does pharmaceutical-grade ATBC compare with industrial-grade ATBC?

The chemical molecule is the same, but commercial grades may differ in controls and documentation. Pharmaceutical customers typically evaluate:

• Assay and impurity profile
• Water content
• Color and odor
• Acid value and ester composition
• Residual solvents
• Elemental impurities
• Microbial limits where applicable
• Packaging and storage controls
• Change-notification procedures
• Good Manufacturing Practice documentation

Industrial-grade material may be technically suitable in some non-pharmaceutical applications but lacks the documentation or quality controls needed for drug-product qualification. The economic premium for pharmaceutical-grade supply is therefore tied to compliance infrastructure, testing, traceability, and supply assurance, not only chemical production cost.

What factors are driving ATBC market growth?

The main growth drivers are regulatory substitution, polymer innovation, and demand for flexible materials.

Phthalate substitution

ATBC benefits from efforts to reduce or avoid certain phthalate plasticizers in consumer, medical, and pharmaceutical products. The substitution case is strongest where customers seek citrate chemistry, low volatility, or a nonphthalate profile.

Substitution is not automatic. A reformulation must preserve coating performance, drug release, stability, manufacturability, and regulatory acceptability. Switching plasticizers can alter polymer permeability and mechanical properties, creating development and stability work.

Growth in modified-release dosage forms

Enteric and modified-release products use polymer coatings to control drug release. ATBC can support the flexibility and film integrity of these systems. Demand therefore tracks the development and lifecycle management of oral solid dosage products, including generic reformulations and line extensions.

Expansion of pharmaceutical manufacturing in Asia

India and China are important centers for generic-drug production, contract development, and contract manufacturing. Growth in these markets supports regional demand for pharmaceutical coating excipients, while local producers place price pressure on established multinational suppliers.

Medical and consumer-product demand

The larger financial driver may be outside pharmaceuticals. Flexible medical materials, food-contact packaging, cosmetics, and specialty coatings can consume more ATBC than drug products. A supplier with broad end-market exposure is less dependent on pharmaceutical development cycles.

What factors could limit ATBC growth?

ATBC competes with other plasticizers, including tributyl citrate, triethyl citrate, polyethylene glycol derivatives, acetylated glycerides, and proprietary plasticizer systems. The optimal choice depends on the coating polymer and formulation objective.

Key constraints include:

• Limited public clinical or product-level visibility for excipient demand
• Qualification costs for new suppliers
• Long change-control cycles at pharmaceutical manufacturers
• Potential batch-to-batch differences in odor, color, or impurity profile
• Competition from lower-cost regional producers
• Exposure to citric acid, n-butanol, acetic acid, energy, and freight costs
• Customer concentration among coating-material manufacturers
• Need for regulatory documentation across multiple jurisdictions

A formulation that already uses ATBC may remain with the incumbent supplier because changing the source can trigger comparability work, stability testing, and regulatory review. That creates retention value for qualified suppliers, but it also slows new-volume conversion.

What is the financial trajectory for acetyl tributyl citrate suppliers?

The financial trajectory is likely to be steady rather than high growth in pharmaceutical applications. Revenue potential depends on portfolio breadth and customer conversion more than on large volume expansion in a single drug product.

Near-term trajectory

Near-term supplier performance is likely to reflect:

• Stable demand from existing coating and capsule applications
• Price competition from Asian producers
• Margin pressure from raw-material and freight volatility
• Increased customer requests for nonphthalate and regulatory documentation
• Inventory normalization after periods of supply-chain disruption

Specialty suppliers with validated pharmaceutical grades can defend pricing better than commodity producers. Distributors may experience lower margins but benefit from inventory, regional supply, and documentation services.

Medium-term trajectory

Medium-term growth is linked to:

• Generic-drug reformulation
• New modified-release products
• Expansion of contract manufacturing
• Increased use of nonphthalate plasticizers
• New medical-device and packaging applications
• Supplier consolidation or strategic partnerships

The strongest commercial position belongs to suppliers that combine global manufacturing, pharmaceutical-quality systems, technical support, and alternate production sites. A low-cost producer without documentation and change-control capability may win industrial volume but face difficulty converting regulated pharmaceutical customers.

Financial sensitivity

Variable	Effect on ATBC economics
Citric acid and n-butanol prices	Direct effect on production cost
Energy prices	Affects esterification, distillation, and utilities
Freight rates	Important for globally traded liquid chemicals
Pharmaceutical qualification	Raises switching costs and supports retention
Industrial plasticizer demand	Can improve plant utilization
Regional competition	Pressures pricing and margins
Regulatory preference for nonphthalates	Supports long-term demand
Customer concentration	Increases contract and volume risk

Because manufacturers do not normally disclose ATBC revenue, investors should assess product-family sales, citrate-ester utilization, specialty-chemical margins, and exposure to pharmaceutical and medical customers instead of seeking a standalone ATBC line item.

What patents and intellectual-property barriers protect ATBC?

ATBC itself is an established chemical substance, so composition-of-matter patent protection is not the principal commercial barrier. The more relevant barriers are operational and formulation-based.

Potentially protectable areas include:

• Improved esterification or acetylation processes
• Purification methods
• Low-color or low-odor grades
• Reduced residual solvent profiles
• Formulations combining ATBC with specific coating polymers
• Drug-release systems using ATBC at defined concentration ranges
• Packaging or delivery systems containing ATBC
• Supplier-specific analytical methods and quality controls

A patent search should distinguish patents that merely list ATBC among dozens of optional excipients from claims that require ATBC in a defined composition. Broad lists may have limited blocking value. Narrow claims tied to a specific polymer, drug, ratio, coating weight, or dissolution profile can be more commercially relevant.

Geographic coverage matters. The same formulation patent may have different enforceability and expiry dates in the United States, Europe, China, India, Japan, and other markets. Pharmaceutical customers should screen both formulation patents and supplier process patents before adopting a second source.

What litigation, licensing, and settlement risks affect ATBC?

ATBC has no inherent Paragraph IV, biosimilar, or Orange Book litigation profile. Litigation risk is generally indirect and product-specific.

Relevant disputes could involve:

• Infringement claims over a coated dosage form
• Trade-secret claims involving purification or manufacturing
• Supply agreements and quality failures
• Regulatory misrepresentation
• Product contamination or specification disputes
• Contractual restrictions on alternate sourcing

Licensing arrangements are more likely to concern a finished dosage form, coating technology, or polymer system than ATBC itself. Public financial disclosures generally do not isolate ATBC licensing revenue or settlement payments.

What generic launch risks exist for ATBC-containing products?

For a generic drug using ATBC, the primary risk is not access to ATBC. The risk is proving that the finished product has the required performance while avoiding valid formulation or method-of-use claims.

A generic manufacturer may face:

1. A formulation patent covering the drug-polymer-plasticizer combination.
2. A method-of-use patent linked to a release profile.
3. Supplier qualification delays.
4. Batch variability that affects dissolution or coating performance.
5. Regulatory review of excipient concentration or route precedent.
6. Commercial dependence on a single qualified supplier.

ATBC can support a design-around if a competitor’s patent requires another plasticizer. The reverse also applies: if a patent claims a broad class of citrate esters, substituting ATBC may not avoid infringement.

How strong is the ATBC patent and commercial estate?

The direct patent estate for the molecule is weak because ATBC is an established chemical. The commercial estate is stronger at the supply-chain and formulation level.

Estate component	Relative strength	Reason
ATBC composition patent	Low	Established substance
Manufacturing process	Moderate	Process conditions and purification may be differentiated
Pharmaceutical formulation	Moderate to high	Depends on claim specificity and remaining term
Supplier qualification	Moderate	Creates practical switching costs
Regulatory documentation	Moderate	Supports customer retention
Brand and technical support	Moderate	Relevant for regulated customers
Manufacturing scale	Moderate to high	Can lower cost and improve supply assurance

What is the outlook for ATBC revenue and investment exposure?

ATBC is best viewed as a specialty excipient and industrial chemical with pharmaceutical optionality, not as a standalone pharmaceutical growth asset. The investment case depends on the supplier’s total citrate-ester portfolio, manufacturing utilization, geographic reach, and ability to sell into regulated applications.

The most attractive commercial profile combines:

• A validated pharmaceutical grade
• Multiple production locations
• Strong impurity and change-control documentation
• Exposure to medical, food-contact, and pharmaceutical applications
• Low dependence on one customer or region
• Technical support for coating and modified-release development

The weaker profile is a single-site commodity producer exposed to price competition and raw-material volatility. Pharmaceutical demand can improve margins, but its volume is unlikely to dominate the broader ATBC market.

Key Takeaways

• ATBC is a nonphthalate citrate-ester plasticizer used in pharmaceutical coatings and other regulated materials.
• It is not an FDA-approved drug and has no standalone Orange Book, Paragraph IV, biosimilar, or Hatch-Waxman exclusivity status.
• Public sources do not provide a reliable standalone pharmaceutical ATBC market size or supplier revenue breakdown.
• Pharmaceutical demand is smaller than the combined industrial, packaging, medical, cosmetic, and food-contact market.
• Growth is supported by phthalate substitution, modified-release dosage forms, and pharmaceutical manufacturing expansion in Asia.
• Pricing and margins depend on raw materials, quality documentation, supply reliability, and regional competition.
• The strongest barriers are supplier qualification, formulation know-how, process control, and customer switching costs.
• ATBC molecule patents are less important than formulation, manufacturing-process, and finished-product patents.
• Supplier financial exposure should be assessed through citrate-ester portfolios and specialty-chemical performance rather than standalone ATBC sales.

FAQs

Is acetyl tributyl citrate an active pharmaceutical ingredient?

No. ATBC is an excipient and plasticizer used in selected dosage-form and delivery-system applications.

Is acetyl tributyl citrate listed in the FDA Inactive Ingredient Database?

FDA database status must be evaluated by dosage form, route, and concentration. An entry, where present, does not authorize unrestricted use in every pharmaceutical product (U.S. Food and Drug Administration, n.d.-a).

Is acetyl tributyl citrate safer than phthalate plasticizers?

ATBC is used as a nonphthalate alternative, but suitability remains dependent on exposure, route, concentration, impurity profile, and the finished-product risk assessment.

Which companies are the main global ATBC suppliers?

Vertellus and Jungbunzlauer are established citrate-ester suppliers. Asian manufacturers and regional distributors provide additional capacity and price competition (Vertellus, n.d.; Jungbunzlauer, n.d.).

Can a generic-drug manufacturer freely substitute ATBC for another plasticizer?

No. The substitution may require formulation development, stability and dissolution testing, supplier qualification, regulatory assessment, and a review of formulation-patent claims.

References

1. European Medicines Agency. (2015). Guideline on the excipients in the label and package leaflet of medicinal products for human use. https://www.ema.europa.eu/

2. Jungbunzlauer. (n.d.). Citrate esters and specialty citrate products. https://www.jungbunzlauer.com/

3. U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda

5. U.S. Pharmacopeia. (2023). General chapter <1059>: Excipient performance. United States Pharmacopeial Convention.

6. Vertellus. (n.d.). Citroflex citrate ester plasticizers. https://vertellus.com/